Antibodies taken from alpacas are to be used in a new pandemic flu drug, in a £33 million project led by AstraZenica.

CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

Scinai Immunotherapeutics (NASDAQ: SCNI) , announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing P ...

CEPI is partnering with Astrazeneca plc to advance VHH-based multispecific antibodies targeting influenza, while Harbour Biomed Ltd. has entered into a global strategic collaboration with Astrazeneca ...

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...

VHH antibodies were first identified in camels in the 1980s, and they have already been used in some therapies to target chronic disease – including cancer and Alzheimer’s.

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, ...

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...